Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Founder Selldown Sends Pro Medicus (ASX:PME) Shares Down 9%

The Pro Medicus Limited (ASX:PME) share price has dropped over 9% after its management sold some shares. 

The Pro Medicus Limited (ASX: PME) share price has dropped over 9% after its management sold some shares.

Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.

Pro Medicus’ Founder Selldown

Over a year and a half ago the company announced that its Board had encouraged the Pro Medicus founders to consider selling up to 3 million shares each so that liquidity of the company’s shares could be improved.

However, any sales were to be made in the company’s normal trading windows after the announcements of the financial results in February and August, or after the annual general meeting (AGM) in November.

That’s why on 20 March 2018 the company was advised that the founders had sold 1 million shares each.

Today, Pro Medicus announced that the founders have sold a further 1 million shares each during the current trading window.

But the Board was also advised that the founders don’t intend to sell any more shares before the trading period which follows the half year results in Februrary 2020 and even then may not do so at that time.

CEO and Co-Founder Sam Hupert sold his 1 million shares at $36.10 per share, meaning he just cashed in a cool $36 million, although there will probably be some tax to pay on that.

What Does This Mean?

It’s important to keep in mind that the two founders still own around ~50% of the company’s shares — equivalent to over $900 million worth of their wealth, each!

Still, it’s perhaps not surprising that management decided to sell some shares because the Pro Medicus share price was trading at a very high valuation.

Interest rates are indeed lower than they were at the start of the year, but the Pro Medicus share price has gone up 203% in 2019 and it’s at an extremely high price/earnings ratio of 188 times the 2019 earnings.

Pro Medicus is a wonderful business with very high profit margins, but we’ve got to be careful about the price we pay – I’m not a buyer today. I also would want to diversify my wealth if a lot of my money was in just Pro Medicus shares, as the founders have done.

But I’d want to put the money towards other good growth shares, like the ones in the free report below.

[ls_content_block id=”18457″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content